Rehabilitation of Facial Emotion Recognition in Alzheimer's Disease
NCT ID: NCT05267028
Last Updated: 2023-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
16 participants
OBSERVATIONAL
2022-02-10
2023-03-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective is to confirm that facial emotion recognition can be improved in AD using the "Training of Affect Recognition program" (TAR).
The Secondary Objectives are to:
Evaluate the impact of the "Training of Affect Recognition program" (TAR) on oculomotor behavior in a situation of social cognition, on behavioral disorders and on caregiver burden.
Confirm that improvement in facial emotion recognition is related to modification of observation strategies.
Confirm the link between improved recognition of facial emotions, reduced behavioral disorders and caregiver burden.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Follow-up of Patients Included in the EYE-TAR(MA) Study.
NCT05254873
Identification of Early Markers of Alzheimer's Disease by Using Eye Tracking in Reading.
NCT02557464
Spatial and Ocular Trajectories for the Early Diagnosis of Alzheimer's Disease.
NCT06213766
Preventing Alzheimer's With Cognitive Training
NCT03848312
Reminiscence, Anxiety and Early Alzheimer's Disease
NCT02319681
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AD-TAR
AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
AD-TAR
12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
AD-Cognitive Stimulation
AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
AD-Cognitive Stimulation
12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-TAR
12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
AD-Cognitive Stimulation
12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* AD diagnosed according to l'IWG-2 (Dubois \& al. 2014) criteria,
* Mini-Mental State (MMS-E) ≥15
* Subject accompanied by a family caregiver and whose participation in a cognitive stimulation workshop was recommended in Memory Centre of the RAINIER Centre (Princesses Grace Hospital - Monaco)
* Written informed consent signed by patient and family caregiver.
Exclusion Criteria
* History of psychiatric and/or neurological disorder (other than the diagnosed neurodegenerative pathology);
* History of alcoholism or drug addiction
* Ophthalmological or neurological problems preventing a video-oculography examination.
* Oculomotor disorders such as "fixation disorders" or "ocular tracking disorders".
* Cognitive disorders of the neurovisual type (visual agnosia, prosopagnosia, visuo-spatial disorder or visuo-perceptual disorder) or aphasia.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Princesse Grace
OTHER
Universite Cote d'Azur
OTHER
Association de Recherche Bibliographique pour les Neurosciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sandrine LOUCHART DE LA CHAPELLE, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Mémoire, Centre de Gérontologie Clinique RAINIER III, Princess Grace Hospital, Monaco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital
Monaco, , Monaco
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EYE-TAR(AD+)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.